Old Web
English
Sign In
Acemap
>
authorDetail
>
P. Schwarzenberger
P. Schwarzenberger
Merck & Co.
Oncology
Pembrolizumab
Medicine
Internal medicine
Phases of clinical research
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC
2021
Journal for ImmunoTherapy of Cancer
Matthew D. Hellmann
Byoung Chul Cho
Rosalyn A. Juergens
Ying Cheng
Gilberto de Castro
Mustafa Erman
Jessica Bauman
Toshiaki Takahashi
P. Schwarzenberger
P Zhang
M. Catherine Pietanza
James Chih-Hsin Yang
Show All
Source
Cite
Save
Citations (0)
P17.01 KEYNOTE-407 China Extension Final Analysis: Pembrolizumab Plus Chemotherapy for the Treatment of Metastatic Squamous NSCLC
2021
Journal of Thoracic Oncology
Ying Cheng
Lifan Zhang
Jie Hu
Donglin Wang
Chengping Hu
Jiaojiao Zhou
Lin Wu
Lejie Cao
Jiwei Liu
Helong Zhang
H. Sun
Z. Wang
Hongjun Gao
Yuping Sun
Ben Li
P. Schwarzenberger
L. Paz-Ares
Show All
Source
Cite
Save
Citations (0)
P14.01 Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC
2021
Journal of Thoracic Oncology
Matthew D. Hellmann
Byoung Chul Cho
Rosalyn A. Juergens
Ying Cheng
G. De Castro
Mustafa Erman
Jessica Bauman
Tiago Kenji Takahashi
P. Schwarzenberger
P Zhang
M.C. Pietanza
J.C-H. Yang
Show All
Source
Cite
Save
Citations (0)
1